Background
Methods
Epidemiology of advanced RCC in Spain
Base case | Sensitivity analysis | References | ||
---|---|---|---|---|
Parameter
|
Lower limit
|
Upper limit
| ||
Kidney cancer incidence 40+ (per 100,000) | 19.8 | 17.82 | 21.78 | [22] |
RCC incidence (over kidney cancer incidence) | 90% | 85% | 95% | |
RCC incidence at diagnosis (over RCC incidence) | 20% | 15% | 25% | |
RCC mortality (localized disease) | 1.66% | 1.49% | 1.83% | [23] |
Transition to advanced RCC (year 1) | 13.18% | 11.86% | 14.49% | [20] |
Transition to advanced RCC (years 2 and 3) | 4.57% | 4.11% | 5.02% | [20] |
Transition to advanced RCC (years 4 and 5) | 1.92% | 1.73% | 2.11% | [20] |
Transition to advanced RCC (year 6 and 7) | 1.64% | 1.48% | 1.81% | [20] |
Transition to advanced RCC (year 8 to 10) | 1.26% | 1.13% | 1.38% | [20] |
Advanced RCC of favorable or intermediate risk | 89% | 80.1% | 97.9% | [26] |
Transition to post-advanced RCC | 100% |
Cost analysis
Budget impact analysis
Sensitivity analysis
Results
Patients | Pazopanib | Sunitinib | Difference | Percent | |
---|---|---|---|---|---|
Per patient and cycle pharmacological costs | €4,046 | €4,904 | -€858 | -17.50% | |
Per patient annual (8 cycles) pharmacological costs | €32,365 | €39,232 | -€6,867 | -17.50% | |
Per patient annual costs associated with AE management | €662 | €974 | -€312 | -32.03% | |
Per patient overall annual costs | €33,027 | €40,206 | -€7,179 | -17.85% | |
Year 2013
| |||||
Advanced RCC at diagnosis | 854 | ||||
Progressions to advanced RCC | 934 | ||||
Advanced RCC (favorable or intermediate risk) | 1,591 | ||||
Pharmacological costs | €29,350,968 | €35,578,198 | -€6,227,230 | -17.50% | |
Overall costs | €30,404,210 | €37,127,832 | -€6,723,622 | -18.11% | |
Year 2014
| |||||
Advanced RCC at diagnosis | 866 | ||||
Progressions to advanced RCC | 948 | ||||
Advanced RCC (favorable or intermediate risk) | 1,615 | ||||
Pharmacological costs | €28,925,945 | €35,063,000 | -€6,137,056 | -17.50% | |
Overall costs | €29,963,935 | €36,590,195 | -€6,626,260 | -18.11% | |
Year 2015
| |||||
Advanced RCC at diagnosis | 878 | ||||
Progressions to advanced RCC | 962 | ||||
Advanced RCC (favorable or intermediate risk) | 1,638 | ||||
Pharmacological costs | €28,483,391 | €34,526,553 | -€6,043,162 | -17.50% | |
Overall costs | €29,505,501 | €36,030,382 | -€6,524,881 | -18.11% |
Unit cost | Pazopanib | Sunitinib | Cost difference | ||||
---|---|---|---|---|---|---|---|
Adverse event | Value | Reference | Incidence | Per patient cost | Incidence | Per patient cost | |
Anorexia
| [28] | €4.97 | €4.97 | €0.00 | |||
Grades I and II | €13.43 | 36% | 34% | ||||
Grade III | €13.43 | 1% | 3% | ||||
Diarrhea
| [28] | €127.12 | €161.01 | -€33.89 | |||
Grades I and II | €6.05 | 54% | 49% | ||||
Grade III | €1,376.13 | 9% | 7% | ||||
Grade IV | €6,171.42 | 1% | |||||
Fatigue
| [28] | €0.89 | €1.02 | -€0.13 | |||
Grades I and II | €1.62 | 44% | 45% | ||||
Grade III | €1.62 | 10% | 17% | ||||
Grade IV | €1.62 | 1% | 1% | ||||
Hand-foot syndrome
| [29] | €23.30 | €52.20 | -€28.90 | |||
Grades I and II | €51.87 | 23% | 38% | ||||
Grade III | €189.41 | 6% | 11% | ||||
Grade IV | €1,165.50 | 1% | |||||
Hypertension
| Expert judgment | €33.72 | €32.88 | €0.84 | |||
Grades I and II | €16.88 | 30% | 25% | ||||
Grade III | €16.88 | 15% | 15% | ||||
Grade IV | €2,612.71 | 1% | 1% | ||||
Nausea
| [28] | €52.28 | €52.59 | -€0.31 | |||
Grades I and II | €31.24 | 43% | 44% | ||||
Grade III | €1,942.30 | 2% | 2% | ||||
Laboratory abnormality
| |||||||
Anemia
| [28] | €65.77 | €126.91 | -€61.14 | |||
Grades I and II | €200.26 | 29% | 53% | ||||
Grade III | €261.70 | 1% | 6% | ||||
Grade IV | €507.46 | 1% | 1% | ||||
ALT
| Expert judgment | €136.70 | €79.77 | €56.93 | |||
Grades I and II | €119.30 | 43% | 38% | ||||
Grade III | €236.16 | 15% | 4% | ||||
Grade IV | €2,498.64 | 2% | 1% | ||||
Neutropenia
| [28] | €138.00 | €248.60 | -€110.60 | |||
Grades I and II | €356.78 | 32% | 48% | ||||
Grade III | €356.78 | 4% | 19% | ||||
Grade IV | €955.53 | 1% | 1% | ||||
Trombocitopenia
| [28] | €78.83 | €214.13 | -€135.30 | |||
Grades I and II | €139.29 | 37% | 56% | ||||
Grade III | €449.54 | 3% | 18% | ||||
Grade IV | €1,380.29 | 1% | 4% | ||||
Total
|
€661.58
|
€974.08
|
-€312.50
|